Dynavax Technologies Corp (NASDAQ: DVAX) reported Q1 EPS of ($0.11), in-line with the analyst estimate of ($0.11). For the quarter ended March 31, 2013, Dynavax reported total revenues of $2.1 million compared to $2.4 million for the quarter ended ...

New York, NY -- (SBWIRE) -- 04/28/2013 -- Growing Stock Report expands its NASDAQ Decliners Weekly Watch List adding Dynavax Technologies Corporation (NASDAQ:DVAX), Nanosphere, Inc. (NASDAQ:NSPH), and Delcath Systems, Inc.

Dynavax Technologies Corporation (NASDAQ:DVAX) a clinical-stage biopharmaceutical company that discovers and develops novel products to prevent and treat infectious and inflammatory diseases is currently down (-3.20%) on 897,308 shares traded.

New York, NY - (NISMAGAZINE) - 04/05/2013- Dynavax Technologies Corporation (NASDAQ:DVAX) rose 5.48% at $2.31 after trading 1.34 million shares.

New York, NY - (NISMAGAZINE) - 05/05/2013- Dynavax Technologies Corporation (NASDAQ:DVAX) shows bullish trend since it made an upward movement of 5.48% with trading volume of 1.34 million shares, in contrast to the 30 days average daily trading ...

New York, NY - (NISMAGAZINE) - 04/26/2013- Dynavax Technologies Corporation (NASDAQ:DVAX) plunged by 4.00% after opening at $2.92, throughout the stock traded in a band of $2.42 and $2.48.

New York, NY - (NISMAGAZINE) - 04/28/2013- Cincinnati Bell Inc. (NYSE:CBB) plunged 3.07% and closed to $3.47. The stock recorded the volume of 1.56 million shares.

Dynavax Technologies Corporation(NASDAQ:DVAX) ended higher 2.89% and completed the day at $2.49. The total number of shares that changed hands during the day was 1.99 million.

Dynavax Technologies Corporation ( DVAX ) suffered a loss of 11 cents per share in the first quarter of 2013, wider than the Zacks Consensus Estimate of a loss of 10 cents per share but flat year over year.

(RTTNews.com) - biopharmaceutical company Dynavax Technologies Corporation ( DVAX ) said it appointed Eddie Gray as chief executive officer and a member of its board, effective May 1, 2013.